文献速递眼底病与葡萄膜炎

Archway 随机 3 期试验:雷珠单抗端口给药系统治疗新生血管性年龄相关性黄斑变性

Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2021-09-29

Archway 3 期开放标签随机对照试验纳入 418 例既往接受过抗 VEGF 治疗的新生血管性年龄相关性黄斑变性患者,比较雷珠单抗端口给药系统每 24 周补充交换与每月雷珠单抗 0.5 mg 注射的疗效与安全性。结果显示 PDS Q24W 在 36 与 40 周平均 BCVA 变化上非劣效且等效于每月注射,98.4% 的 PDS 患者首次补充交换前未接受补充治疗,但预设眼部特殊不良事件在 PDS 组更常见。

要点

  • PDS Q24W 在 36 与 40 周平均 BCVA 变化上非劣效且等效于每月雷珠单抗注射。
  • 98.4% 的 PDS 治疗患者在首次补充交换前未接受补充雷珠单抗治疗。
  • PDS 组预设眼部特殊不良事件发生率 19.0%,高于每月注射组的 6.0%。

核心结论

  • PDS Q24W 达到主要终点,在 36 与 40 周平均 BCVA 变化上非劣效且等效于每月雷珠单抗注射。
  • 98.4% 的 PDS 治疗患者在首次 24 周补充交换间隔内未接受补充雷珠单抗治疗。
  • PDS 组预设眼部特殊不良事件发生率高于每月雷珠单抗组,且多数发生在植入后 1 个月内。

研究设计与样本

  • 3 期、开放标签、随机、视力评估者设盲的非劣效性与等效性试验。
  • 纳入筛查前 9 个月内诊断且既往接受抗 VEGF 治疗并有应答的新生血管性年龄相关性黄斑变性患者。
  • 患者按 3:2 随机分配至 PDS 雷珠单抗 100 mg/ml 固定每 24 周补充交换组或每月雷珠单抗 0.5 mg 玻璃体腔注射组。
  • Archway 试验共纳入 418 例患者,PDS Q24W 组 251 例随机、248 例接受治疗,每月雷珠单抗组 167 例随机并接受治疗。

主要发现

  • 基线 BCVA 在 PDS Q24W 组为 74.4 字母,在每月雷珠单抗组为 75.5 字母(Snellen 等效 20/32)。
  • 36 与 40 周平均 BCVA 较基线变化在 PDS Q24W 组为 +0.2 字母(SE 0.5 字母),在每月雷珠单抗组为 +0.5 字母(SE 0.6 字母),差异为 -0.3 字母(95%CI -1.7 至 1.1 字母)。
  • 在 246 例接受 PDS 治疗并评估补充雷珠单抗的患者中,242 例(98.4%)在首次补充交换操作前未接受补充雷珠单抗治疗,包括 4 例在首次补充交换前终止治疗的患者。
  • 预设眼部特殊不良事件在 PDS Q24W 组报告于 47 例(19.0%)患者,在每月雷珠单抗组报告于 10 例(6.0%)患者;PDS 组包括 4 例(1.6%)眼内炎、2 例(0.8%)视网膜脱离、13 例(5.2%)玻璃体出血、6 例(2.4%)结膜糜烂和 5 例(2.0%)结膜退缩。
  • PDS Q24W 组大多数眼部不良事件发生在植入后 1 个月内。

关键数值与推荐

  • 主要终点为 36 与 40 周平均 BCVA ETDRS 字母评分较基线变化,非劣效界值为 -4.5 字母,等效界值为 ±4.5 字母。
  • PDS Q24W 组 36 与 40 周平均 BCVA 变化 +0.2 字母,每月雷珠单抗组 +0.5 字母,差异 -0.3 字母(95%CI -1.7 至 1.1 字母),满足非劣效与等效标准。
  • PDS 组 98.4%(242/246)评估患者在首次补充交换前未接受补充雷珠单抗治疗。
  • PDS 组预设眼部特殊不良事件发生率 19.0%(47 例),每月雷珠单抗组 6.0%(10 例)。

临床怎么用

  • 对于既往抗 VEGF 治疗有应答的新生血管性年龄相关性黄斑变性患者,PDS Q24W 可作为每 24 周补充交换的替代方案,疗效与每月雷珠单抗注射相当。
  • 使用 PDS 时需关注植入后 1 个月内的眼部不良事件,包括眼内炎、视网膜脱离、玻璃体出血、结膜糜烂和结膜退缩。
  • 多数 PDS 患者在首次 24 周间隔内无需补充雷珠单抗治疗,但仍需按方案进行补充交换操作。

局限性

  • 试验为开放标签设计,视力评估者设盲,患者和研究者在分组上未设盲。
  • 随访报告截至 36 与 40 周主要终点及首次 24 周间隔内补充治疗情况,未提供更长期数据。
  • 预设眼部特殊不良事件在 PDS 组发生率较高,且多数发生在植入后 1 个月内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). DESIGN: Phase 3, open-label, randomized, visual acuity assessor-masked noninferiority and equivalence trial. PARTICIPANTS: Patients with nAMD diagnosed within 9 months of screening previously treated with and responsive to anti-vascular endothelial growth factor therapy. METHODS: Patients were randomized 3:2 to treatment with the PDS with ranibizumab 100 mg/ml with fixed 24-week (Q24W) refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab). MAIN OUTCOME MEASURES: Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, ±4.5 letters). RESULTS: Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab. Baseline BCVA was 74.4 letters (PDS Q24W arm) and 75.5 letters (monthly ranibizumab arm; Snellen equivalent, 20/32). Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference, -0.3 letters; 95% confidence interval, -1.7 to 1.1 letters). PDS Q24W was both noninferior and equivalent to monthly ranibizumab. Of 246 PDS-treated patients assessed for supplemental ranibizumab treatment, 242 (98.4%) did not receive supplemental ranibizumab treatment before the first refill-exchange procedure, including 4 patients who discontinued treatment before the first refill-exchange procedure. Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions. Most ocular adverse events in the PDS Q24W arm occurred within 1 month of implantation. CONCLUSIONS: Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Holekamp NM, Campochiaro PA, Chang MA, et al. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021. PMID: 34597713. doi:10.1016/j.ophtha.2021.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。